The optimal dose of dexmedetomidine as a 0.59% ropivacaine adjuvant for epidural anesthesia in great saphenous varicose vein surgery, based on hemodynamics and anesthesia efficacy: a randomized, controlled, double-blind clinical trial

This study aimed to explore the optimal dose of dexmedetomidine as a 0.59% ropivacaine adjuvant for epidural anesthesia on perioperative hemodynamics and anesthesia efficacy in patients undergoing great saphenous varicose vein surgery. A total of 90 patients were randomly divided into three groups:...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in medicine 2024-07, Vol.11, p.1426512
Main Authors: Zeng, Sisi, Li, Xuechao, Xu, Hongchun, Ye, Qin, Li, Zhaogang, Wang, Fangjun
Format: Article
Language:English
Subjects:
anesthetic effect
dexmedetomidine
epidural anesthesia
hemodynamics
Medicine
ropivacaine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to explore the optimal dose of dexmedetomidine as a 0.59% ropivacaine adjuvant for epidural anesthesia on perioperative hemodynamics and anesthesia efficacy in patients undergoing great saphenous varicose vein surgery. A total of 90 patients were randomly divided into three groups: 0.25 μg/kg dexmedetomidine combined with 0.59% ropivacaine epidural infusion group (ED group), 0.5 μg/kg dexmedetomidine combined with 0.59% ropivacaine epidural infusion group (ED group), and 0.75 μg/kg dexmedetomidine combined with 0.59% ropivacaine epidural infusion group (ED group). Hemodynamics, anesthesia efficiency, and adverse reactions were recorded. Compared with the ED group, the ED group had lower systolic blood pressure at T (T , 95%CIs, 6.52-21.93,  
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2024.1426512